Appl. No. 10/631,809
Response dated March 28, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:   10/631,809   )
)
Applicants: Chee-Keung Chung et al.   )   TC/A.U.:   1654
)
Filed: August 1, 2003   )   Examiner: Christopher R. Tate
)
Title: EFFECTS OF SPORODERM-   )   Customer No.:
               BROKEN GERMINATION   )
               ACTIVATED GANODERMA   )   *23639*
               SPORES ON TREATMENT OF   )   PATENT TRADEMARK OFFICE
               SPINAL CORD INJURY   )
)
Docket No.:   GR7040542001   )
               (formerly 33229 -182586)   )

Honorable Commissioner for Patents
Alexandria, VA 22313
Mail Stop Non-Fee Amendment

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

The owner, Enhan Technology Holdings International Co., Ltd., of 100% percent interest in

the instant application hereby disclaims, except as provided below, the terminal part of the statutory

term defined in 35 U.S.C. 154 and 173 as shortend by any terminal disclaimer filed prior to the

grant of any patent granted on pending second Application Number 10/752,685, filed on January 8,

2004, of any patent on the pending second application. The owner hereby agrees that any patent

so granted on the instant application shall be enforceable only for and during such period that it and

any patent granted on the second application are commonly owned. This agreement runs with any

patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent

granted on the instant application that would extend to the expiration date of the full statutory term

DCDOCS/622169.1

Appl. No. 10/631,809
Response dated March 28, 2005

as defined in 35 U.S.C. 154 and 173 of any patent granted to said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either 1 or 2 below, if appropriate.

1.   ___   For submissions on behalf of a business organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

    I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issued thereon.

2.   X   The undersigned is an attorney of record. Reg. No. __43,538__
    X   The Commissioner is hereby authorized to charge the amount of $65.00 for payment of the terminal disclaimer fee as required by 37 CFR 1.20 (d) to, or any additional fees due to, or credit any overpayment to Deposit Account No. 50-2518.
    X   PTO suggested wording for terminal disclaimer was
        X   unchanged.
        __   changed (if changed, an explanation should be supplied).

DCDOCS/622189.1

Facsimile

DATE: March 28, 2005

Bingham McCutchen LLP
Suite 800
1120 20th Street, NW
Washington, DC
20036-3406

202.778.6150
202.778.6155 fax

bingham.com

Boston
Hartford
London
Los Angeles
New York
Orange County
San Francisco
Silicon Valley
Tokyo
Walnut Creek
Washington

	NAME	FAX	PHONE
TO:	Examiner Christopher Tate USPTO	703-872-9306	
FROM:	Fei-Fei Chao fei-fei.chao@bingham.com	(202) 778-6155	(202) 419-2252

PAGES: (INCLUDING THIS COVER PAGE):

RE: Terminal Disclaimer for U.S. Application No.: 10/631,809

MESSAGE:

Dear Examiner Tate,

Based on our telephone conversation of March 28, 2005, I hereby submit a terminal disclaimer for the current pending application. This will confirm our discussion that the current application will be in condition of allowance.

Please feel free to contact me should you have any additional questions.

Thank you.

Timekeeper No:	33306	Client/Matter No:		DATE/TIME STAMP
Client/Matter Name:				
Return To:			Floor No:	08

Appl. No. 10/631,809
Response dated March 28, 2005

Respectfully submitted,

Date: <u>March 28, 2005</u>

<u>*Fei-Fei Chao*</u>

Fei-Fei Chao, Ph.D. (Reg. No. 43,538)
Bingham McCutchen LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111-4067
Tel.: (202) 778-3179
Fax: (202)-778-6155